☆ 4.6 Review

Efficacy and safety of COVID-19 inactivated vaccine: A meta-analysis

FRONTIERS IN MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy

Mona Ariamanesh et al.

Summary: The study confirmed the safety and short-term efficacy of the inactivated SARS-CoV-2 vaccine in cancer patients, with an overall seroconversion rate of 86.9%. However, the conversion rate was lower in older age groups, those with hematological malignancies, and recipients of chemotherapy.

CANCER INVESTIGATION (2022)

添加到收藏夹

Meeting Abstract Oncology

A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?

S. A. Javadinia et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Infectious Diseases

Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study

Eric Yuk Fai Wan et al.

Summary: The study evaluated the risk of Bell's palsy after vaccination with BNT162b2 and CoronaVac, finding an increased risk of Bell's palsy following CoronaVac vaccination. However, the overall benefits and protective effects of the inactivated COVID-19 vaccine far outweigh the risk of this generally self-limiting adverse event.

LANCET INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Clinical Neurology

Case Report: Anti-NF186+CIDP After Receiving the Inactivated Vaccine for Coronavirus Disease (COVID-19)

Shirui Wen et al.

Summary: Coronavirus disease 2019 (COVID-19) is a global pandemic, and vaccination can decrease mortality rate. This article reports a rare case of NF186+ CIDP in a patient who received an inactivated COVID-19 vaccine, highlighting potential rare side effects and the clinical effectiveness of rituximab in treating patients with this condition.

FRONTIERS IN NEUROLOGY (2022)

添加到收藏夹

Review Endocrinology & Metabolism

COVID-19 Vaccination in Patients With Malignancy; A Systematic Review and Meta-Analysis of the Efficacy and Safety

Seyed Alireza Javadinia et al.

Summary: This paper assessed the efficacy and safety of COVID-19 vaccines in cancer patients through a systematic review and meta-analysis. The results showed that the overall seroconversion rates after receiving a second dose of COVID-19 vaccine were 88% for patients with solid tumors and 70% for patients with hematologic malignancies. Therefore, it can be concluded that COVID-19 vaccination in patients with active malignancies is highly effective, safe, and well-tolerated.

FRONTIERS IN ENDOCRINOLOGY (2022)

添加到收藏夹

Review Medicine, General & Internal

Immunogenicity and Safety of COVID-19 Vaccines in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis

Becky Mingyao Ma et al.

Summary: Patients on renal replacement therapy, especially kidney transplant recipients, showed significantly reduced antibody response after receiving two doses of COVID-19 vaccine. The use of mycophenolate was negatively associated with seropositivity.

FRONTIERS IN MEDICINE (2022)

添加到收藏夹

Article Surgery

Drug-induced hepatitis after Sinopharm COVID-19 vaccination: A case study of a 62-year-old patient

Hossein Ghorbani et al.

Summary: This article presents a case of hepatitis induced by the Sinopharm COVID-19 vaccine. A 62-year-old male developed jaundice, weight loss, and elevated liver enzymes three days after receiving the second dose of the vaccine. Microscopic examination revealed a pattern of hepatitis injury with inflammation in both the portal and lobular regions, as well as significant eosinophil infiltration.

INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS (2022)

添加到收藏夹

Article Public, Environmental & Occupational Health

A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report

Nahide Onsun et al.

Summary: A 72-year-old male psoriasis patient developed generalized pustular psoriasis flare after receiving the CoronoVac vaccine, making him the first reported psoriasis patient to experience an erythrodermic flare following vaccination.

HEALTH PROMOTION PERSPECTIVES (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Raches Ella et al.

Summary: The study reported the clinical efficacy of the BBV152 vaccine against COVID-19 infection in Indian adults. The vaccine demonstrated high efficacy in preventing laboratory-confirmed symptomatic COVID-19 and was well tolerated with no safety concerns raised in this interim analysis.

LANCET (2021)

添加到收藏夹

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhiwei Wu et al.

Summary: The study showed that CoronaVac vaccine is safe and well tolerated in older adults, and is able to induce neutralizing antibody levels. The highest dose of 3 μg of the vaccine can generate neutralizing antibody levels similar to the 6 μg dose, supporting the use of the 3 μg dose CoronaVac in phase 3 trials.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang et al.

Summary: This study investigated the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate CoronaVac, and found that the 3 μg dose showed higher seroconversion rates in the phase 2 trial.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Immunology

International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples

Eric Robinson et al.

Summary: The global willingness to uptake COVID-19 vaccines is decreasing while refusal to vaccinate is increasing. Factors such as gender, age, lower income and education levels, and belonging to ethnic minority groups are associated with lower intentions to vaccinate.

VACCINE (2021)

添加到收藏夹

Letter Dermatology

Herpes zoster following inactivated COVID-19 vaccine: A coexistence or coincidence?

Ecem Bostan et al.

JOURNAL OF COSMETIC DERMATOLOGY (2021)

添加到收藏夹

Review Immunology

Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis

Nadim Sharif et al.

Summary: This study conducted a meta-analysis on the efficacy of COVID-19 vaccines, revealing that mRNA vaccines and adenovirus vector vaccines can provide moderate to high protection against COVID-19 in individuals aged 18 and above. However, evidence on the long-term protection of these vaccines in individuals under 16 years old against multiple variants of COVID-19 is limited.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Emergency Medicine

Type 1 Kounis Syndrome Induced by Inactivated SARS-COV-2 Vaccine

Ibrahim Halil Ozdemir et al.

Summary: This case report presents a rare occurrence of Kounis syndrome following inactivated coronavirus vaccine administration in a 41-year-old woman. The patient developed symptoms of flushing, palpitation, dyspnea, and chest pain after vaccination, with ECG changes and elevated Troponin-I levels. Coronary angiography showed no signs of coronary atherosclerosis. This case highlights the importance of monitoring and awareness of potential allergic reactions, such as Kounis syndrome, following COVID-19 vaccination.

JOURNAL OF EMERGENCY MEDICINE (2021)

添加到收藏夹

Review Immunology

Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Ali Pormohammad et al.

Summary: This study systematically reviewed the clinical features of COVID-19 vaccines in clinical trials, finding that mRNA-based and adenovirus-vectored vaccines exhibited different efficacy and side effect profiles. Both types of vaccines showed high efficacy after the first and second doses, with mRNA-based vaccines having higher reported side effects.

VACCINES (2021)

添加到收藏夹

Letter Dermatology

Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: A report of two cases

Ecem Bostan et al.

DERMATOLOGIC THERAPY (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial

Nawal Al Kaabi et al.

Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Letter Dermatology

Herpes zoster after inactivated SARS-CoV-2 vaccine in two healthy young adults

A. K. Ozdemir et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Mine Durusu Tanriover et al.

Summary: The study presented the interim efficacy and safety results of the CoronaVac vaccine in a phase 3 clinical trial in Turkey, demonstrating high efficacy against PCR-confirmed symptomatic COVID-19 with good safety and tolerability profile. Results showed significant differences in the frequency of any adverse events between the vaccine and placebo groups, indicating excellent protective effects of the vaccine.

LANCET (2021)

添加到收藏夹

Article Immunology

A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia

Eddy Fadlyana et al.

Summary: The study assessed the efficacy, safety, and immunogenicity of an inactivated SARS-CoV-2 vaccine. The interim analysis showed a 65.30% efficacy in preventing COVID-19 illness, with favorable safety and immunogenicity profiles.

VACCINE (2021)

添加到收藏夹

Article Ophthalmology

Association of Ocular Adverse Events With Inactivated COVID-19 Vaccination in Patients in Abu Dhabi

Francesco Pichi et al.

Summary: A case series study of 7 patients who experienced ocular adverse events after receiving an inactivated COVID-19 vaccine showed transient ocular complications occurring on average 5.2 days post-vaccination, including episcleritis, anterior scleritis, acute macular neuroretinopathy, and others.

JAMA OPHTHALMOLOGY (2021)

添加到收藏夹

Review Immunology

Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical Trials

Jiaxin Chen et al.

Summary: The study found that NMAEs (nervous and muscular adverse events) after COVID-19 vaccination are common, particularly headache and myalgia. Although these adverse events are mostly mild reactions, continuous monitoring is still necessary during the vaccination process.

VACCINES (2021)

添加到收藏夹

Article Immunology

Randomized, Double-Blinded, Placebo-Controlled Phase 2 Trial of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in Healthy Adults

Yanchun Che et al.

Summary: This study evaluated an inactivated SARS-CoV-2 vaccine for immunogenicity and safety in adults aged 18-59 years. The results showed that vaccinated adults developed neutralizing antibodies as well as anti-S/N antibodies with a low rate of adverse reactions.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials

Hong-Xing Pan et al.

Summary: This study reported the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults. The vaccine demonstrated good tolerability and induced robust immune responses in both phase 1 and phase 2 trials.

CHINESE MEDICAL JOURNAL (2021)

添加到收藏夹

Review Medicine, General & Internal

A Comprehensive Review of Coronavirus Disease 2019: Epidemiology, Transmission, Risk Factors, and International Responses

Han Li et al.

Summary: The COVID-19 pandemic originated in Wuhan, China, has rapidly spread globally, causing millions of confirmed cases and hundreds of thousands of deaths worldwide. Despite the complex clinical presentation and diagnosis of the disease, effective epidemiological understanding and control measures are crucial.

YONSEI MEDICAL JOURNAL (2021)

添加到收藏夹

Article Immunology

Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry

Mojca Bizjak et al.

IMMUNOLOGIC RESEARCH (2017)

添加到收藏夹

Editorial Material Medicine, General & Internal

Vaccine Hesitancy

Robert M. Jacobson et al.

MAYO CLINIC PROCEEDINGS (2015)

添加到收藏夹

Article Immunology

Vaccine hesitancy: Definition, scope and determinants

Noni E. MacDonald

VACCINE (2015)

添加到收藏夹

Article Medicine, General & Internal

New Decade of Vaccines 5 Addressing the vaccine confidence gap

Heidi J. Larson et al.

LANCET (2011)

添加到收藏夹

Article Medicine, General & Internal

Severe necrotizing pancreatitis following combined hepatitis A and B vaccination

Eran Shlomovitz et al.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.